End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
86,600 KRW | -1.93% | +3.96% | -13.75% |
30/01 | SK Biopharmaceuticals Swings to Profit in Q4 | MT |
2023 | SK Group Advances Net Zero Transition via Key Renewable Energy Deal | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 212.19 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-13.75% | 5.05B | A- | ||
+5.48% | 69.91B | A | ||
+12.55% | 9.24B | A- | ||
+42.38% | 4.47B | - | ||
+4.51% | 3.92B | B- | ||
-19.05% | 2.41B | C- | ||
-28.72% | 2.23B | - | ||
+11.13% | 2.02B | - | - | |
+5.20% | 1.66B | D+ | ||
-0.50% | 1.64B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A326030 Stock
- Ratings SK Biopharmaceuticals Co., Ltd.